This Brain Cancer Awareness Month, the Olivia Newton-John Cancer Research Institute (ONJCRI) proudly celebrates the vision and leadership of Prof Hui Gan, whose newly established Cancer Therapies and Biology Laboratory is shaping bold advances in brain cancer research and care.
Driving Change
Prof Gan’s passion for improving patient outcomes is personal. “I need something better for my patients,” he says, underscoring a deep commitment to finding solutions for one of the most aggressive and devastating cancers. His work is already at the forefront of two landmark initiatives: the LUMOS-2 trial and the PRECISE study, both of which are being led out of ONJCRI and are critical to advancing brain cancer research in Australia.
The LUMOS-2 trial builds on the success of its predecessor, LUMOS, which pioneered the use of genomic profiling in patients with recurrent glioblastoma – the most common and deadliest form of brain cancer. LUMOS-2 is taking this a step further by refining precision medicine approaches, aiming to match patients with treatments based on their tumour’s unique molecular characteristics. This personalised approach could revolutionise how glioblastoma is treated and significantly improve outcomes for patients who currently face limited options.
The PRECISE study focuses on developing and validating advanced imaging and biomarker tools to better monitor brain cancer progression and treatment response. By integrating cutting-edge imaging with molecular data, the study aims to provide clinicians with real-time insights, helping to tailor therapies more effectively and identify early signs of treatment success or failure.
A Bright Future for Australian Research
Prof Gan is clear-eyed about the challenges ahead but resolute in his belief that real change will come from within Australia’s research community. “Progress for Australian patients with brain cancer will be impacted more by national efforts than by serendipitous discoveries overseas,” he explains, emphasising the urgent need for coordinated, well-funded national research initiatives.
He also sees immense potential in the growing collaboration between scientists and clinicians. “Integrated multi-disciplinary research and clinical platforms will accelerate progress for patients,” Prof Gan advises, highlighting his lab’s mission to bridge laboratory discoveries with clinical practice.
As the brain cancer community unites this month to raise awareness, Prof Gan offers a hopeful and galvanising message:
“We are at a pivotal time in our nation where there is an opportunity to make real progress through carefully planned coordination of research and trials.”
At ONJCRI, we are proud to stand with Prof Gan and the brain cancer community in striving for a future where patients not only have more treatment options, but better outcomes and longer lives. This Brain Cancer Awareness Month – and every month – we reaffirm our commitment to advancing research that makes a lasting impact.
